Bure Equity Q2 2026: Strong Book Value, Rising Share Value & Optimistic Forecast
Explore Bure Equity’s Q2 2026 gains—boosted by Mycronic, Yubico, and Silex—showing resilient growth, higher book value, and a revised revenue outlook.
2 minutes to read